For Immediate Release

Chicago, IL – August 6, 2009 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Medco Health Solutions (MHS), CVS Caremark Corp (CVS), Express Scripts (ESRX), WellPoint Inc. (WLP) and Whole Foods Market (WFMI).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Wednesday’s Analyst Blog:

Medco Earnings Beat Estimates

Revenues from Medco Health Solutions’ (MHS) specialty pharmacy segment, Accredo Health Group, increased 20.3% to $2.38 billion primarily due to significant addition of new clients and organic growth of the segment.

Based on the robust performance of all the segments, MHS has raised the 2009 earnings guidance. The company revised its earnings guidance to $2.76 – $2.81 (earlier $2.67-$2.77), an increase of 18-21% compared to the year ago period. The strong growth and the positive outlook is more significant in the current scenario where rising unemployment has left many people out of the insurance bracket forcing some PBM’s to lower their outlook.

In another major development, MHS won the business for managing pharmacy benefits for Chrysler’s union retirees from its rival CVS Caremark Corp (CVS). Though MHS is the leading player in the PBM segment, it will face tough challenges once Express Scripts (ESRX) completes its $4.68 billion acquisition of health insurer WellPoint Inc. (WLP), making the combined entity another major player.

Whole Foods Outperforms

Whole Foods Market (WFMI) recently reported better-than-expected third quarter 2009 results with low single-digit growth in both the top-line and bottom-line. EPS came in at 25 cents, surpassing the Zacks Consensus Estimate of 19 cents, and up 4.2% year over year compared to 24 cents reported in the prior-year quarter, driven by stringent cost-control measures and improved store-level performance.

On account of the better-than-expected results, management raised its full-year earnings outlook. The company now expects fiscal year 2009 EPS in the range of 80 cents to 82 cents, up from 65 cents to 70 cents forecasted earlier. For the fourth quarter 2009, EPS is expected to be in the range of 16 cents to 18 cents.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research